glp-1 and cardiovascular benefits Glucagon-like peptide 1 receptor agonists: mechanisms of action Cardiovascular benefits of obesity therapies:

Although DPP-4 inhibitors do not cross the BBB under normal conditions (the pharmacokinetic feature may prevent their repurposing use in neurodegenerative diseases), the permeability of BBB is increased in neurodegenerative diseases, so molecules otherwise unable to cross BBB could enter into CNS in these conditions (103)

Nakamura et al., 2025)

In late-stage trials, people taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks , and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control

Garlic and onions: their cancer prevention properties